TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 3049116
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered to 25 patients with Hodgkin's disease (control group).
Study: 31370791
Drug: New treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: New treatment
Study: 23595003
Drug: 1250 μg/week
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1250 μg/week (50 000 IU/week, analysed dose 1544 μg/week) followed by 1250 μg/month
Study: 21636116
Drug: omalizumab (75-375
Approvals — FDA: no, EMA: no, PMDA: no
Description: omalizumab (75-375 mg, subcutaneously once every 2 or 4 weeks for 24 weeks)
Study: 31682972
Drug: LPS administration
Normalized name: LP-20
Approvals — FDA: no, EMA: no, PMDA: no
Description: LPS administration
Study: 11268375
Drug: Chronic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chronic treatment with antidepressants (imipramine or fluoxetine)
Study: 2478336
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg ketoprofen
Study: 3512149
Drug: 650 mg
Normalized name: bran 650 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 650 mg acetaminophen
Study: 10561210
Drug: Oral medroxyprogesterone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral medroxyprogesterone acetate 200 mg/d
Study: 8739857
Drug: multiple injections
Normalized name: sodium acetate
Approvals — FDA: yes, EMA: no, PMDA: no
Description: multiple injections of insulin alone
Study: 1928949
Drug: Albuterol followed
Normalized name: Albuterol
DrugBank: Albuterol (DB01001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albuterol followed by saline
Study: 25086831
Drug: Ocular Response
Normalized name: Besponsa
DrugBank: Inotuzumab ozogamicin (DB05889)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ocular Response Analyzer (ORA) with Nelfilcon A (Daily AquaComfort Plus)
Study: 17196453
Drug: Statin therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statin therapy with LDL <100 mg/dl
Study: 9822313
Drug: 0.5 microg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 microg/kg subcutaneous octreotide
Study: 24859203
Drug: Vedolizumab (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vedolizumab (300 mg)
Study: 20439065
Drug: Calcium/vitamin D
Normalized name: CALCIUM/VITAMIN D
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium/vitamin D supplement
Study: 20439065
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D supplement only
Study: 20439065
Drug: Antiosteoporosis medications
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiosteoporosis medications
Study: 12954916
Drug: Cholesterol-reducing drugs
Normalized name: Cholesterol
DrugBank: Cholesterol (DB04540)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholesterol-reducing drugs
Study: 1407926
Drug: Subcutaneous and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous and oral terbutaline
Study: 28816242
Drug: Basimglurant 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basimglurant 1.5 mg
Study: 27604770
Drug: DHA (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHA (400 mg/day)
Study: 7748048
Drug: Ibuprofen and
Normalized name: Ibuprofen and Famotidine Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen and Naproxen
Study: 24250318
Drug: Bupivacaine wound
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine wound infiltration (40 ml, 0.25%)
Study: 24250318
Drug: Saline control
Normalized name: GLYCERIN 0.53 g in 1 mL CUTANEOUS INJECTION [Glycerol-Saline Control]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline control (40 ml, 0.9%)
Study: 21336630
Drug: Acetyl-L-carnitine (ALC)
Normalized name: acetyl-L-carnitine
DrugBank: Acetylcarnitine (DB08842)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetyl-L-carnitine (ALC) plus methylphenidate (20-30 mg/day depending on weight)
Study: 1425865
Drug: lansoprazole 30
Normalized name: lansoprazole 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: lansoprazole 30 mg
Study: 10485504
Drug: lansoprazole 15
Normalized name: lansoprazole 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: lansoprazole 15 mg
Study: 8792693
Drug: lansoprazole 30
Normalized name: lansoprazole 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: lansoprazole 30 mg vs lansoprazole 15 mg
Study: 8792693
Drug: omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: omeprazole 20 mg vs lansoprazole 15 mg
Study: 6735042
Drug: 40 749
Normalized name: petrolatum 0.749 MG/MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 749 RP 4 mg/kg
Study: 30198967
Drug: 0.5mg ranibizumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5mg ranibizumab monthly for 12 months
Study: 15818420
Drug: Scheme I:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scheme I: tetracycline 500 mg qid, furazolidone 100 mg qid, colloidal bismuth subcitrate 120 mg qid for 3 days
Study: 15818420
Drug: Scheme II:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scheme II: tetracycline 500 mg qid, furazolidone 100 mg qid, colloidal bismuth subcitrate 120 mg qid for 4 days
Study: 15818420
Drug: Treatment (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment (both schemes)
Study: 2035858
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg of preservative-free morphine in 1.0 mL of 0.9% saline added to local anesthetic solution (20 mL of 1% plain lignocaine, 20 mL of 0.5% plain bupivacaine) with intramuscular placebo injection of 1.0 mL of 0.9% saline
Study: 2035858
Drug: 1.0 mL
Normalized name: digoxin 0.25 mg in 1.0 mL INTRAVENOUS INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 mL of 0.9% saline added to local anesthetic solution with intramuscular injection of 5 mg of preservative-free morphine in 1.0 mL of 0.9% saline
Study: 31646981
Drug: nal-IRI (mg/m2,
Approvals — FDA: no, EMA: no, PMDA: no
Description: nal-IRI (mg/m2, 46h infusion)/5-FU (2400 mg/m2, 46h infusion)/leucovorin (400 mg/m2, 0.5h infusion) d1 on 14 day-cycles
Study: 30261853
Drug: 12-week multimodal
Normalized name: risedronate
DrugBank: Risedronic acid (DB00884)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 12-week multimodal intervention including supervised exercise training, home-based walking, supportive nurse-led counseling, and protein supplement after training.
Study: 30415608
Drug: Standard oncological
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard oncological treatment
Study: 8750372
Drug: Hydrochlorothiazide 12.5
Normalized name: hydrochlorothiazide 12.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrochlorothiazide 12.5 mg alone
Study: 1665181
Drug: Combination tablet
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination tablet of lisinopril and hydrochlorothiazide
Study: 26377913
Drug: Opioid combination
Normalized name: Opioids in combination with antispasmodics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Opioid combination
Study: 19476015
Drug: Desloratadine 5.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desloratadine 5.0 mg qd
Study: 19476015
Drug: Pseudoephedrine 120
Normalized name: CTM 8/PSEUDOEPHEDRINE 120MG SA CAP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pseudoephedrine 120 mg bid
Study: 17179911
Drug: No test
Approvals — FDA: no, EMA: no, PMDA: no
Description: No test solution (Control group)
Study: 7723267
Drug: Traditional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional treatment (emergency operation in peritonitis or nonoperative management with cleansing enema, purgatives, and infusion-transfusion therapy)
Study: 7723267
Drug: Emergency colonoscopy
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Emergency colonoscopy and ultrasonic diagnosis with fractional oral treatment using 30% solution of polyethylene oxide-400 and 1% chloramphenicol
Study: 2521934
Drug: Felodipine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Felodipine (5 mg x2/day for 2 weeks, then 10 mg x2/day)
Study: 31660826
Drug: Pharmacokinetic AUC‐based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacokinetic AUC‐based chemotherapy
Study: 31660826
Drug: BSA guided
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BSA guided chemotherapy
Study: 23873171
Drug: HPV16/18 vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: HPV16/18 vaccine
Study: 19326811
Drug: Piper longum
Normalized name: piper longum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piper longum (15 mg)
Study: 19326811
Drug: Piper longum
Normalized name: piper longum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piper longum (30 mg)
Study: 15298338
Drug: Insulin detemir/insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin detemir/insulin aspart
Study: 11515348
Drug: Lansoprazole suspension
Normalized name: Lansoprazole
DrugBank: Lansoprazole (DB00448)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lansoprazole suspension (30 mg via nasogastric tube)
Study: 11515348
Drug: Lansoprazole intact
Normalized name: Lansoprazole
DrugBank: Lansoprazole (DB00448)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lansoprazole intact capsule
Study: 11515348
Drug: Lansoprazole suspension
Normalized name: Lansoprazole
DrugBank: Lansoprazole (DB00448)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lansoprazole suspension and intact capsule
Study: 10351117
Drug: LW 50020
Approvals — FDA: no, EMA: no, PMDA: no
Description: LW 50020 (Luivac; Paspat oral), taken once daily for two periods of 4 weeks each, with a treatment-free interval of 4 weeks.
Study: 18367956
Drug: Bolus recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bolus recombinant factor VIII (rFVIII) 25 to 50 IU/kg given 6, 14, 24, 36, 48, and 60 hours after loading dose
Study: 17138770
Drug: Mifepristone, 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mifepristone, 5 mg daily for 26 weeks
Study: 638119
Drug: Daily supplements
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily supplements of 20-30 mg inorganic iron as ferrous sulphate for 3.5, 7, and 12 months
Study: 17469936
Drug: Modafinil (1.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modafinil (1.75 mg/kg, 3.50 mg/kg, or 7.00 mg/kg)
Study: 17469936
Drug: d-Amphetamine (0.035
Approvals — FDA: no, EMA: no, PMDA: no
Description: d-Amphetamine (0.035 mg/kg, 0.070 mg/kg, 0.140 mg/kg)
Study: 9809846
Drug: Glutamine supplementation
Normalized name: Glutamine
DrugBank: L-Glutamine (DB00130)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glutamine supplementation (100 mg x kg(‐1) administered at 0, 30, 60, and 90‐min post‐race)
Study: 18221638
Drug: Omega-3 fatty
Normalized name: Omega-3 fatty acid
DrugBank: Omega-3 fatty acids (DB11133)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omega-3 fatty acids supplemented diet (EPA + DHA, enriched in salmon 150 g/day, 3 times/week)
Study: 9783928
Drug: Sequential therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential therapy with mitomycin C (40 mg) followed by BCG (6 weekly instillations)
Study: 9783928
Drug: Mitomycin C
Normalized name: Mitomycin C
DrugBank: Mitomycin (DB00305)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mitomycin C only (10 weekly instillations)
Study: 7848896
Drug: Immediate-release isosorbide
Normalized name: isosorbide Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate-release isosorbide dinitrate (ISDN) 15-120 mg in a qid regimen
Study: 7848896
Drug: Asymmetric tid
Normalized name: An asymmetric immunoglobulin G1 (IgG1)-based, B-cell maturation antigen (BCMA) x CD3 T-cell bispecific monoclonal antibody
Approvals — FDA: no, EMA: no, PMDA: no
Description: Asymmetric tid therapy with 30 mg of ISDN (7 a.m., 1 p.m., and 6 p.m.)
Study: 7848896
Drug: Asymmetric bid
Normalized name: An asymmetric immunoglobulin G1 (IgG1)-based, B-cell maturation antigen (BCMA) x CD3 T-cell bispecific monoclonal antibody
Approvals — FDA: no, EMA: no, PMDA: no
Description: Asymmetric bid therapy with ISDN at 7 a.m. and noon
Study: 7848896
Drug: Immediate-release isosorbide-5-mononitrate
Normalized name: Isosorbide 5-mononitrate
DrugBank: Isosorbide mononitrate (DB01020)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Immediate-release isosorbide-5-mononitrate (IS-5-MN) 10 and 20 mg given bid
Study: 7848896
Drug: Once-daily controlled-release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily controlled-release IS-5-MN
Study: 3140580
Drug: 17 alpha-hydroxyprogesterone
Normalized name: 17 alpha-hydroxyprogesterone
Approvals — FDA: no, EMA: no, PMDA: no
Description: 17 alpha-hydroxyprogesterone caproate (17HPC, Proluton Depot) 500 mg intramuscularly weekly for 6-16 weeks
Study: 3140580
Drug: 17 alpha-hydroxyprogesterone
Normalized name: 17 alpha-hydroxyprogesterone
Approvals — FDA: no, EMA: no, PMDA: no
Description: 17 alpha-hydroxyprogesterone caproate (17HPC) 500 mg intramuscularly weekly
Study: 3140580
Drug: 17 alpha-hydroxyprogesterone
Normalized name: 17 alpha-hydroxyprogesterone
Approvals — FDA: no, EMA: no, PMDA: no
Description: 17 alpha-hydroxyprogesterone caproate (17HPC) 250 mg intramuscularly weekly
Study: 3140580
Drug: Contraceptive pill
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Contraceptive pill (Microgynon)
Study: 30036596
Drug: Patients with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with ACE inhibitor-associated angioedema
Study: 30036596
Drug: ACE inhibitor-treated
Normalized name: ACE INHIBITORS
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACE inhibitor-treated controls
Study: 26871954
Drug: Corticosteroid injection
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroid injection (1 ml of 40 mg/ml methylprednisolone dissolved in 4 ml lidocaine)
Study: 26871954
Drug: Placebo injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo injection (1 ml isotonic saline mixed with 4 ml lidocaine)
Study: 22708259
Drug: Rapid titration
Normalized name: Abreva Rapid Pain Relief
DrugBank: Glycerin (DB09462)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rapid titration
Study: 15076242
Drug: Nucleoside analogue
Normalized name: Nucleoside analogue
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nucleoside analogue treatment; venous lactate measured according to AACTG guidelines.
Study: 9669015
Drug: Chloromycetin ointment
Normalized name: chloroacetate
DrugBank: Chloramphenicol succinate (DB07565)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chloromycetin ointment (group O)
Study: 3278390
Drug: Radiation concurrent
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Radiation concurrent with cisplatinum
Study: 3278390
Drug: Twice a
Normalized name: Pataday Twice A Day Relief
DrugBank: Olopatadine (DB00768)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Twice a day irradiation with 120 cGys up to 6,000 cGys
Study: 15103479
Drug: Systemic antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic antibiotic treatment
Study: 23184140
Drug: Biological material
Normalized name: Microbiological material
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biological material TOT (PELVILACE® TO)
Study: 18394162
Drug: Drotrecogin alfa
Normalized name: Drotrecogin Alfa
DrugBank: Drotrecogin alfa (DB00055)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drotrecogin alfa (activated; DrotAA) at a dosage of 24 mug/kg per hour for 96 hours
Study: 1785247
Drug: Oral atropine
Normalized name: atropine Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral atropine 0.03 mg/kg (Group A)
Study: 1785247
Drug: i.v. glycopyrrolate
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. glycopyrrolate 0.005 mg/kg (Group G)
Study: 24758078
Drug: Ginkgo Leaves
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ginkgo Leaves Tablet (GLT), 19.2 mg each time, three times daily for 12 months
Study: 6189039
Drug: Responders to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Responders to chemotherapy
Study: 387151
Drug: Standard dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dose flupenthixol decanoate
Study: 387151
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose flupenthixol decanoate
Study: 30273016
Drug: Oral nutrition
Normalized name: BAGS/TUBES/SUPPLIES FOR ORAL NUTRITION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral nutrition supplementation (ONS) for 7 days before surgery
Study: 26811519
Drug: Etoposide 50
Normalized name: etoposide 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etoposide 50 mg/m2 and cisplatin 50 mg/m2 plus concurrent thoracic radiation therapy (60 to 66 Gy) followed by two cycles of consolidation platinum-based doublet chemotherapy (arm B)
Study: 9038463
Drug: Glycopyrrolate 0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycopyrrolate 0.3 mg
Study: 22243938
Drug: Hypertonic saline
Normalized name: ENTSOL Hypertonic Saline Nasal Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypertonic saline solution (HSS)
Study: 18544724
Drug: Melatonin (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin (2.5 mg)
Study: 18544724
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment (bright light + melatonin)
Study: 15780736
Drug: High-dose combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose combined hepatitis A and B vaccine administered in two doses (0, 6 months)
Study: 15780736
Drug: Paediatric-dose combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paediatric-dose combined hepatitis A and B vaccine administered in three doses (0, 1, 6 months)
Study: 14504024
Drug: Three-session motivational
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three-session motivational enhancement therapy (MET alone)
Study: 1627421
Drug: Breast-conserving therapy
Normalized name: chicken breast preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Breast-conserving therapy (lumpectomy, axillary clearance, and radiotherapy to the breast: 50 Gy external irradiation in 5 weeks followed by boost with iridium implant of 25 Gy)
Study: 6744790
Drug: Dopamine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dopamine infusion at 0.01 micrograms min‐1 kg‐1
Study: 6744790
Drug: Dopamine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dopamine infusion at 0.1 micrograms min‐1 kg‐1
Study: 29242000
Drug: Social recovery
Normalized name: Chem-Star Recover
Approvals — FDA: no, EMA: no, PMDA: no
Description: Social recovery therapy plus early intervention services
Study: 11976161
Drug: xoi gac
Normalized name: Xoimenia americana seed extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: xoi gac (3.5 mg beta-carotene per serving)
Study: 11976161
Drug: rice mixed
Normalized name: Rice
DrugBank: Rice (DB10563)
Approvals — FDA: no, EMA: no, PMDA: no
Description: rice mixed with synthetic beta-carotene powder (5.0 mg)
Study: 8890080
Drug: Commercial available
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Commercial available preterm infant formula (2% protein, 40 mg glycine/dl)
Study: 6391269
Drug: Fentanyl infusion
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fentanyl infusion (2 micrograms/kg/hour)
Study: 24074777
Drug: Response-guided approach
Normalized name: Besponsa
DrugBank: Inotuzumab ozogamicin (DB05889)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Response-guided approach for hormone-positive tumors
Study: 24074777
Drug: Increasing number
Normalized name: Derma Numb
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Increasing number of chemotherapy cycles
Study: 24074777
Drug: Adding bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Adding bevacizumab in TNBC treatment
Study: 8258986
Drug: Mechanical pressure
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mechanical pressure therapy (MPT)
Study: 24655114
Drug: no infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: no infusion
Study: 24655114
Drug: oesophageal acid
Normalized name: Cellspan Esophageal Implant
DrugBank: Cellspan Esophageal Implant (DB18688)
Approvals — FDA: no, EMA: no, PMDA: no
Description: oesophageal acid infusion
Study: 19939872
Drug: Org 26828
Normalized name: ORG-34517
DrugBank: ORG-34517 (DB05423)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Org 26828 at higher doses
Study: 18369631
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of radiographic features
Study: 12522402
Drug: Prophylactic injection
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic injection of bupivacaine with adrenaline
Study: 10643842
Drug: Palivizumab (monoclonal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Palivizumab (monoclonal antibody to the F protein of RSV)
Study: 21211651
Drug: Low-dose fluticasone
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose fluticasone
Study: 17845685
Drug: H(2) antagonist
Normalized name: Interleukin-1 receptor antagonist anakinra
DrugBank: Anakinra (DB00026)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: H(2) antagonist + furazolidone + one other antibiotic
Study: 17845685
Drug: Bismuth-based triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bismuth-based triple therapies
Study: 11524192
Drug: Topical anesthesia
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical anesthesia plus intracameral lidocaine 1%
Study: 8568016
Drug: Nicoderm (nicotine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicoderm (nicotine transdermal system), 21 mg/day applied for 24 hours
Study: 8568016
Drug: Controlled smoking
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controlled smoking (30 cigarettes at half‐hourly intervals on days 1 and 5; ad libitum smoking on days 2‐4)
Study: 28633671
Drug: Prucalopride 2
Normalized name: prucalopride 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prucalopride 2 mg/day
Study: 26251066
Drug: Amoxicillin combined
Normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amoxicillin combined with sulbactam
Study: 24001747
Drug: Vitamin D3
Normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D3 (50-μg/d)
Study: 12954158
Drug: Losartan (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan (50 mg daily for 12 months)
Study: 2160516
Drug: 10^4 PFU
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10^4 PFU dose of rhesus rotavirus vaccine
Study: 2160516
Drug: 10^3 PFU
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10^3 PFU dose of rhesus rotavirus vaccine
Study: 31917835
Drug: Somapacitan 0.16
Approvals — FDA: no, EMA: no, PMDA: no
Description: Somapacitan 0.16 mg/kg/wk